Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025, after the close of the U.S. financial markets. The ...
Investor's Business Daily on MSN2h
Investing Action Plan: A Big Week For Biotechs, Pharma And Econ, Plus Amazon And AlphabetThe week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and ...
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake ...
We recently compiled a list of the 7 Cheap Quarterly Dividend Stocks to Invest in. In this article, we are going to take a ...
Amgen (NASDAQ:AMGN – Free Report) had its price target decreased by Citigroup from $310.00 to $295.00 in a research report released on Tuesday morning,Benzinga reports. Citigroup currently has a ...
In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a ...
Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.
Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...
On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...
Amgen Inc (AMGN) stock saw a decline, ending the day at $280.3 which represents a decrease of $-2.65 or -0.94% from the prior close of $282.95. The stock opened at $280.13 and touched a low of $279.97 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback